Amelioration of Glucose Intolerance by the Synthetic Androstene HE3286: Link to Inflammatory Pathways

Insulin resistance, the major metabolic abnormality underlying type 2 diabetes, is associated with chronic inflammation and heavy macrophage infiltration in white adipose tissue (WAT). The therapeutic properties of the synthetic adrenal steroid Δ5-androstene-17α-ethynyl-3β,7β,17β-triol (HE3286) were characterized in metabolic disease models. Treatment of diabetic db/db mice with HE3286 suppressed progression to hyperglycemia and markedly improved glucose clearance. Similar effects were also observed in insulin-resistant, diet-induced obese C57BL/6J mice and genetically obese ob/ob mice. This effect appeared to be a consequence of reduced insulin resistance because HE3286 lowered blood insulin levels in db/db and ob/ob mice. Treatment with HE3286 was accompanied by suppressed expression of the prototype macrophage-attracting chemokine monocyte chemoattractant protein-1 in WAT, along with its cognate receptor C-C motif chemokine receptor-2. Exposure of mouse macrophages to HE3286 in vitro caused partial suppression of endotoxin (lipopolysaccharide)-induced nuclear factor κ-B (NF-κB)-sensitive reporter gene expression, NF-κB nuclear translocation, and NF-κB/p65 serine phosphorylation. Proinflammatory kinases, including IκB kinase, c-Jun NH2-terminal kinase, and p38, were also inhibited by HE3286. In ligand competition experiments HE3286 did not bind to classical sex steroid or corticosteroid receptors, including androgen receptor (AR), progesterone receptor, estrogen receptor (ER) α or ERβ, and glucocorticoid receptor (GR). Likewise, in cells expressing nuclear receptor-sensitive reporter genes HE3286 did not substantially stimulate transactivation of AR, ER, GR, or peroxisome proliferator-activated receptor (PPAR) α, PPARδ, and PPARγ. These findings indicate that HE3286 improves glucose homeostasis in diabetic and insulin-resistant mice and suggest that the observed therapeutic effects result from attenuation of proinflammatory pathways, independent of classic sex steroid receptors, corticosteroid receptors, or PPARs.

[1]  J. Frincke,et al.  7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases. , 2009, Autoimmunity reviews.

[2]  J. Olefsky,et al.  Insulin sensitivity: modulation by nutrients and inflammation. , 2008, The Journal of clinical investigation.

[3]  Peter Tontonoz,et al.  Integration of metabolism and inflammation by lipid-activated nuclear receptors , 2008, Nature.

[4]  A. Goldfine,et al.  Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes , 2008, Clinical and translational science.

[5]  M. Karin,et al.  JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. , 2007, Cell metabolism.

[6]  A. Hevener,et al.  Macrophage peroxisome proliferator activated receptor γ as a therapeutic target to combat Type 2 diabetes , 2007, Expert opinion on therapeutic targets.

[7]  C. Glass,et al.  Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. , 2007, The Journal of clinical investigation.

[8]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[9]  Y. Tamura,et al.  Amelioration of glucose tolerance by hepatic inhibition of nuclear factor κB in db/db mice , 2006, Diabetologia.

[10]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[11]  Claudio Cobelli,et al.  DHEA in elderly women and DHEA or testosterone in elderly men. , 2006, The New England journal of medicine.

[12]  S. Akira,et al.  Toll-like receptors and innate immunity , 2006, Journal of Molecular Medicine.

[13]  R. Kitazawa,et al.  MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. , 2006, The Journal of clinical investigation.

[14]  R. Leibel,et al.  CCR2 modulates inflammatory and metabolic effects of high-fat feeding. , 2006, The Journal of clinical investigation.

[15]  P. Scherle,et al.  Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344 , 2005, The Journal of Immunology.

[16]  S. B. Pedersen,et al.  Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  A. Hevener,et al.  IKK-β links inflammation to obesity-induced insulin resistance , 2005, Nature Medicine.

[18]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.

[19]  I. Charo,et al.  Chemokines in the pathogenesis of vascular disease. , 2004, Circulation research.

[20]  L Earl Gray,et al.  Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  G. Muscat,et al.  RORalpha regulates the expression of genes involved in lipid homeostasis in skeletal muscle cells: caveolin-3 and CPT-1 are direct targets of ROR. , 2004, The Journal of biological chemistry.

[22]  G. Muscat,et al.  RORα Regulates the Expression of Genes Involved in Lipid Homeostasis in Skeletal Muscle Cells , 2004, Journal of Biological Chemistry.

[23]  Xiaohui S. Xie,et al.  Errα and Gabpa/b specify PGC-1α-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle , 2004 .

[24]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[25]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[26]  D. Loskutoff,et al.  Monocyte chemoattractant protein 1 in obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Glass,et al.  PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Michael Karin,et al.  A central role for JNK in obesity and insulin resistance , 2002, Nature.

[29]  L. Gray,et al.  A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  H. Lardy,et al.  Ergosteroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[32]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[33]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[34]  J. Mariani,et al.  The orphan nuclear receptor RORα is a negative regulator of the inflammatory response , 2001 .

[35]  D. Brenner,et al.  NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. , 1998, The Journal of clinical investigation.

[36]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[37]  R. Simsolo,et al.  The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. , 1995, The Journal of clinical investigation.

[38]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[39]  C. Longcope,et al.  Androgenic and estrogenic metabolites in serum of mice fed dehydroepiandrosterone: relationship to antihyperglycemic effects. , 1987, Metabolism: clinical and experimental.

[40]  D. Coleman,et al.  Effect of Genetic Background on the Therapeutic Effects of Dehydroepiandrosterone (DHEA) in Diabetes-Obesity Mutants and in Aged Normal Mice , 1984, Diabetes.

[41]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. , 2005, Nature medicine.

[42]  Xiaohui Xie,et al.  Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Alimuddin Zumla,et al.  Validation of housekeeping genes for normalizing RNA expression in real-time PCR , 2004 .

[44]  J. Mariani,et al.  The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. , 2001, EMBO reports.